Key features and details
- Mouse monoclonal [9G6] to ErbB 2
- Suitable for: ICC/IF, IHC-Fr, IP, IHC-P, Flow Cyt
- Reacts with: Human
- Isotype: IgG1
Product nameAnti-ErbB 2 antibody [9G6]
See all ErbB 2 primary antibodies
DescriptionMouse monoclonal [9G6] to ErbB 2
Tested applicationsSuitable for: ICC/IF, IHC-Fr, IP, IHC-P, Flow Cytmore details
Species reactivityReacts with: Human
Predicted to work with: Dog
Synthetic peptide corresponding to Human ErbB 2 (C terminal).
Database link: P04626
- SK-BR-3 cells or breast carcinoma tissue
Working dilutions should be stored at +4°C, not refrozen, and preferably used the same day. If a slight precipitation occurs upon storage, this should be removed by centrifugation. It will not affect the performance or the concentration of the product.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. Please see notes section.
Storage bufferPreservative: 0.1% Sodium azide
Constituents: 0.2% Gelatin, 0.82% Sodium phosphate
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab16899 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use at an assay dependent concentration.|
|IHC-Fr||Use a concentration of 5 µg/ml.|
|IP||Use a concentration of 1 µg/ml. Immunoprecipitates 185,000 dalton c-ErbB2/c-neu protein.|
|IHC-P||Use at an assay dependent concentration.|
|Flow Cyt||Use 0.1-1µg for 106 cells.
ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
FunctionProtein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.
In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth.
Tissue specificityExpressed in a variety of tumor tissues including primary breast tumors and tumors from small bowel, esophagus, kidney and mouth.
Involvement in diseaseHereditary diffuse gastric cancer
Chromosomal aberrations involving ERBB2 may be a cause gastric cancer. Deletions within 17q12 region producing fusion transcripts with CDK12, leading to CDK12-ERBB2 fusion leading to truncated CDK12 protein not in-frame with ERBB2.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.
Contains 1 protein kinase domain.
modificationsAutophosphorylated. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit (Probable). Ligand-binding increases phosphorylation on tyrosine residues (PubMed:27134172). Signaling via SEMA4C promotes phosphorylation at Tyr-1248 (PubMed:17554007). Dephosphorylated by PTPN12 (PubMed:27134172).
Cellular localizationCytoplasm. Nucleus and Cell membrane. Cytoplasm, perinuclear region. Nucleus. Translocation to the nucleus requires endocytosis, probably endosomal sorting and is mediated by importin beta-1/KPNB1.
- Information by UniProt
- Verb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog antibody
- C erb B2/neu protein antibody
- CD340 antibody
Overlay histogram showing MCF7 cells stained with ab16899 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab16899, 0.1μg/1x106 cells) for 30 min at 22°C. The secondary antibody used was Alexa Fluor® 488 goat anti-mouse IgG (H+L) (ab150113) at 1/2000 dilution for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 1μg/1x106 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >5,000 events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter. This antibody gave a positive signal in MCF7 cells fixed with 80% methanol (5 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.
ab16899 at 1/100 staining human kidney cells by ICC/IF. The cells were fixed and permeabilized with acetone/methanol before being blocked with 50% serum for 5 minutes at 37°C. The primary antibody was then incubated for 30 minutes at 37°C. An Alexa Fluor® 488 goat anti-mouse antibody was used as the secondary.
ab16899 has been referenced in 4 publications.
- Pietilä M et al. SORLA regulates endosomal trafficking and oncogenic fitness of HER2. Nat Commun 10:2340 (2019). PubMed: 31138794
- Bagdany M et al. Chaperones rescue the energetic landscape of mutant CFTR at single molecule and in cell. Nat Commun 8:398 (2017). PubMed: 28855508
- Gomes de Castro MA et al. Aptamers provide superior stainings of cellular receptors studied under super-resolution microscopy. PLoS One 12:e0173050 (2017). PubMed: 28235049
- van de Vijver MJ et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239-45 (1988). IHC-P . PubMed: 2903446